Xeleris 4 DR

Inform your decisions with measurable results

Xeleris™ 4 DR is the next generation of our proven workstation for nuclear medicine. In the past, Xeleris led the way with mobilized capabilities that gave you accessible, easy-to-use tools to enhance productivity. With your guidance, we designed Xeleris 4 DR to deliver modern, quantitative applications for nuclear medicine; applications like the all-new Q.Volumetrix MI, which gives you the certainty of absolute quantitation in customizable, easy-to-read reports across multiple care areas.

Xeleris 4 DR is leading the way from relative to absolute quantitation in nuclear medicine with the numerical values referring physicians demand to strengthen the quality of your nuclear medicine reports. Until now, the quantitative value of nuclear medicine was limited by the technology used to produce it. By leveraging our next-generation camera technology, we developed a collection of simplified tools that combine relative and absolute quantitation.

• I Effortless quantitative tracer uptake across any lesion or organ with Q.Volumetrix MI
• I Accurately diagnose neurodegenerative diseases with Q.Brain
• I Diagnose pulmonary embolism by identifying V/Q mismatch with Q.Lung
• I Confidently classify patients eligible for lung resection surgeries with Q.Lung

• I Leverage the power of CZT to calculate blood flow measurements with Alcyone CFR
• I Improve neurologic SPECT workflow with fast, reproducible and accurate quantitation of ¹²³ I-loflupane SPECT data with DaTQUANT ^TM
• I Plan radioisotope therapy by measuring changes in tracer absorption over time with Dosimetry Toolkit

Q.Volumetrix MI is the quantitative addition to Volumetrix MI, a processing and reading application that works across modalities and with hybrid imaging. It combines reading, segmentation and quantitative ability in a single application, which can help make SPECT quantitation more routine.

Q.Volumetrix MI quantitates tracer uptake across any lesion and any organ. Utilizing advanced reconstruction with attenuation, scatter and resolution compensation, it provides routine quantitative results without impediment for both base line and longitudinal studies. Enhanced SPECT and CT 2D and 3D segmentation tools make uptake calculations easy for lesions, organs and any other volume of interest.

Volumetrix MI alone delivers clarity, choice and convenience by incorporating two powerful software packages: Volumetrix 3D and Volumetrix IR. This combination allows you to perform multiple types of procedures using only a single application. Now, with these two software packages working together with Q.Volumetrix MI, you get improved image clarity, the choice of an external CT to enhance SPECT studies and all the convenience of optimized registration and quantitation.

SPECT/CT is a highly sensitive and specific diagnostic tool for the assessment of pulmonary embolism, chronic obstructive pulmonary disease, emphysema and other lung deficiencies. It is a low-dose alternative to CTPA with no contrast related complications and it is more accurate than planar VQ studies. With SPECT/CT, we can reduce the overall radiation dose by 80 percent and up to 96 percent for breast tissue, when compared to a CTPA. Additionally, hybrid imaging increases the sensitivity to 97 percent and specificity to 100 percent.

With Q.Lung, you can now accurately display both ventilation and perfusion integrated with the lung atlas in an easily interpretable review screen, which can be customized to your reading preferences. It also helps to easily identify uptake mismatches and automatically calculates its quotient for a more effective way to diagnose pulmonary embolism. It’s a valuable tool to help reduce the 5-10 percent of preventable hospital deaths annually attributed to the misdiagnosis of pulmonary embolism.

For important procedures like lung resection, a reliable assessment of post-operative lung function is essential. With 1.5 million lung cancer deaths a year, uncertain estimations provided by current planar imaging techniques are not enough. It’s the difference between successfully performing a life-saving procedure and denying that procedure to a good candidate.

Breakthrough SPECT/CT technology provides a more accurate assessment of lobar perfusion. Q.Lung combines both anatomy and function with new automatic segmentation tools that help accurately quantitate lobar perfusion relative to the rest of the lung anatomy. The result is a more accurate evaluation of ppoFEV₁

to confidently inform the outcome of segmentectomy, lobectomy or full pneumectomy.

Establishing care early and accurately can lessen the burden and cost of neurodegenerative disease. Patterns are an important part of differential diagnosis, so the more sensitive an imaging device and its advanced processing application is at detecting and visualizing patterns, the more quickly patients can be put on the correct treatment pathway. Q.Brain standardizes individual brain shapes through registration to a standard atlas while preserving functional information. Numeric uptake values are added to reports and compared to a normal patient database since visual inspections or volume-of-interest techniques may not be sufficient for accurate diagnosis. This additional information can improve communication among physicians on care teams, enhancing the value of nuclear medicine in the management of complex brain diseases.

3D SSP images. Early and Late acquisitions. Late acquisition is post Diamox injection

SPECT and MR fused images with quantitative analysis: uptakes and z-scores across all 26 regions of the brain.

When it comes to the heart, relative quantitative results aren’t enough. Current SPECT MPI studies use the area of highest myocardial activity as a reference point for the rest of the perfusion study. If that reference point is also abnormal, it compromises the accuracy of the entire study. In addition, triple vessel disease (balanced ischemia) and microvascular disease don’t always result in an abnormal MPI exam. For years, PET has been a well-established gold standard for MBF exams, but it can be limited by cost and accessibility. Recent advancements in SPECT technology have made it possible to enhance the clinical value of nuclear cardiology.

Alcyone CFR leverages highly sensitive Alcyone SPECT technology in our fully stationary, solid state Discovery™ NM530c system. It calculates coronary flow reserve and myocardial blood flow from a dynamic SPECT acquisition. In addition, it provides absolute quantitative results for both global and regional blood flow. With a wider availability of low-cost SPECT tracers, previously limited to PET technologies, Alcyone CFR provides a real opportunity to explore the benefits of SPECT.

DaTQUANT is an advanced neurologic application that aids in the assessment of dopamine receptor uptake in the caudate and putamen regions of the brain. It enables visual evaluation and quantitation of¹²³

I-Ioflupane SPECT images relative to a normal population database of images from the European Normal Control Database of DaTSCAN (ENC-DAT) study. It automatically calculates striatal binding ratios, putamen/caudate ratios and left-to-right asymmetry. And a built-in report generator provides referring physicians with structured results in an easy-to-read PDF report that clearly communicates the degree of functional DaT loss.

Dosimetry Toolkit is an advanced clinical application that helps you quantify changes in radiopharmaceutical uptake over time. It uses multi-whole-body SPECT/CT and/or whole-body planar data sets to quantify changes. Interactive and semi-automatic tools allow you to segment target organs, delineate activity zones and calculate the volume, activity and residence time per organ. These tools simplify the procedure for quantifying radiopharmaceutical dose, reduce processing time and improve the accuracy of results, compared to manual tools. In addition, Dosimetry Toolkit creates an essential input to other radiotherapy planning software. It’s an advanced application that can help you determine the right dose for radioisotope therapy to begin treatment and accurately adjust it over time.

While the future of nuclear medicine is in quantitative applications, Xeleris 4 DR includes a comprehensive library of clinical applications with additional capabilities to help improve patient care.

These applications include Evolution for Cardiac or Bone, which utilizes Evolution¹

technology to change the relationship between image quality, time and dose, making it possible to change one without impacting another. By applying a resolution recovery algorithm that models the collimator-detector response, Evolution permits up to half the scan time or up to half the dose while delivering the same image quality as from a full-time or full-dose scan. Additionally, with Evolution Toolkit, you can extend the benefits of Evolution to exams that require additional tracers, including¹²³

I,¹³¹

I,²⁰¹

TI,¹¹¹

In and⁶⁷

Ga.

Xeleris 4 DR also includes the DICOM PDF viewer, which allows you to create a PDF report and save it within the Xeleris database in DICOM PDF format. Then, you can send it to any DICOM repository that supports this format and view the report using the PDF Report Viewer application.

Another noteworthy application is the Emory Cardiac Toolbox 4.0. With this application, you get valuable tools like SmartReport²

, which automatically submits images to the American Society of Nuclear Cardiology ImageGuide²

Registry.

With enhanced features that deliver greater access, automated workflow and personalized applications, Xeleris 4 DR is an image management solution that takes advantage of today’s highly mobile technology and puts it to use your way, where, when and how you want it.

The Xeleris Case exchange enables you to share any case from the Xeleris workstation to the Centricity Imaging Collaboration Suite in the GE Health Cloud³

. Each case includes SPECT, PET and CT studies and any related data and can be viewed by other Imaging Collaboration Suite or Case Exchange users.

In addition, Xeleris Floating License frees you from traditional workstations without limiting your productivity or responsiveness. You can remotely access whatever applications you need. You can transfer your full set of applications and images to any PACS system for robust processing and review capabilities. And with Xeleris DICOM viewer, you can easily connect referring physicians to results. Its pre-defined and customizable Auto Capture and Archive take the redundancy out of your workflow. Data and image transfers go from multiple clicks to zero and no interaction is required to have your images and data go where you want.

Your applications are where you do all of your great work, but it’s the technology at the core of your image management system that provides the essential framework for how you work. New technologies at the heart of Xeleris 4 DR make it more reliable, more capable and more secure. These technologies include a new Windows⁴

10 operating system with a collection of security enhancements like antivirus, BitLocker⁴

and whitelisting to protect patient data.

Xeleris 4 DR also supports virtually unlimited display screen resolutions so you can review images on the screen of your choice. And a more robust, 750 GB database with a simplified storage structure keeps all of your data in one database. This collection of infrastructure enhancements elevates the technology central to today’s nuclear medicine experience.

Molecular imaging enables the search for a different kind of discovery. The kind that could have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.

To make a true discovery in nuclear medicine, the applications you use to interpret and communicate information are just as important as the tracers used to highlight that information and the technology used to capture it. In fact, it’s these final measurable results that you ultimately require. To make the true discovery that helps you deliver the best outcome to the patient, or potentially impact the standard of care for all patients, you need the accuracy and consistency of absolute quantitation.

Our vision for molecular imaging is to provide you with the important instruments you need to see and the ability to prove what is seen, and often not seen. It’s why we committed ourselves to bringing you quantitative applications with Xeleris 4 DR.

Let Xeleris 4 DR guide your path to your next true discovery.

• ¹ In clinical practice, Evolution options ^1a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit ^1b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
• ^1a Evolution Options - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
• ^1b Evolution Toolkit - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the images reconstructed with FBP / OSEM.
• ² SmartReport and ImageRegistry are registered trademarks of Syntermed, Inc.
• ³ Case Exchange may not be available in all markets, as it requires GE Health Cloud.
• ⁴ Windows and BitLocker are registered trademarks of Microsoft Corporation.